0000842023 2025-07-01 2026-06-30 0000842023 2025-12-31 0000842023 2026-10-09 iso4217:USD shares false --06-30 2026 FY 0000842023 10-K/A true 2026-06-30 false 0-17272 BIO-TECHNE CORP MN 41-1427402 614 McKinley Place N.E. Minneapolis MN 55413 612 379-8854 Common Stock, $0.01 par value TECH NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false false 9100000000 157055564 true <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Policies and Practices Related to the Timing of Grants of Certain Equity Awards</div> <div><span style="font-weight: bold;"> </span><br/> </div> <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;">The Compensation Committee and senior management monitor the Company’s equity grant practices to evaluate whether such policies comply with governing regulations and are consistent with good corporate practices. <span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;">All annual equity grants are issued effective August 15. When making regular annual equity grants, the Compensation Committee’s practice is to approve them at its meeting in the first quarter each year as part of the annual compensation review and after results for the preceding fiscal year become available. The proximity of any awards to other significant corporate events is coincidental. In addition, the Compensation Committee may make grants at any time during the year it deems appropriate, including with respect to new hires or transitions.</span> <span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;">The Company does not schedule its equity grants in anticipation of the release of material non-public information (“MNPI”) nor does the Company time the release of MNPI based on equity grant dates.<br/> </span></div> <div> <br/> </div> <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;">During fiscal 2026, no stock option grants were made to any of our NEOs during any period beginning four business days before the filing or furnishing of a periodic report or current report and ending one business day after the filing or furnishing of any such report with the SEC.</div> <span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;">All annual equity grants are issued effective August 15. When making regular annual equity grants, the Compensation Committee’s practice is to approve them at its meeting in the first quarter each year as part of the annual compensation review and after results for the preceding fiscal year become available. The proximity of any awards to other significant corporate events is coincidental. In addition, the Compensation Committee may make grants at any time during the year it deems appropriate, including with respect to new hires or transitions.</span> true <span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;">The Company does not schedule its equity grants in anticipation of the release of material non-public information (“MNPI”) nor does the Company time the release of MNPI based on equity grant dates.<br/> </span> true